The MRCF collaboration is innovation in action: We provide a path for taking medical science out of the laboratory and into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we create businesses, run companies and o everything necessary to ensure our investments succeed.
If you are interested in accessing the MRCF for your investment opportunity, please contact the commercialisation office at your institute.
An early-stage fund dedicated to supporting the development and commercialisation of early-stage medical technologies;
Each Member Institute has a representative on the Investment Review Committee (IRC).
If this initial proposal is recommended to progress, a presentation by the key researchers.
If the IRC is supportive of the technology receiving investment, the opportunity is passed to the Brandon Capital Partners.
If Brandon Capital Partners approves an investment opportunity, it recommends to the Board that the investment is made.
Through the internship it was fantastic to understand what Brandon are looking for in the projects they fund. The learnings from the internship program will be applied to the new projects we develop, both in reviewing the opportunity and developing a solid business plan that will increase the commercial success.
The internship was a valuable experience that filled a critical gap in my knowledge of how early-stage life science technologies are commercialised. Up to this point, my experience was from a technology development perspective, and I did not have a full understanding of what investors were seeking in potential investments. The internship experience is immeasurable and will pay dividends well into the future.
The internship was an excellent learning and development opportunity. I greatly improved my understanding of the venture capital financing model and elements such as valuation, due diligence, market analysis and drug development. The MRCF internship program also enabled me to expand my national commercialisation networks and work alongside experienced biotech investors.